Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- David S Miller, MD
University of Texas Southwestern Medical Center, Dallas, USA
Principal Investigator - Hani Gabra, MD
Imperial College London Hammersmith Campus, London, UK
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
123 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Medizinische Universität Innsbruck
Innsbruck, Austria
- Alexandrov National Cancer Centre of Belarus
Minsk, Belarus
- Minsk City Clinical Oncologic Dispensary
Minsk, Belarus
- Mogilev Regional Clinical Oncologic Dispensary
Mogilev, Belarus
- Vitebsk Regional Clinical Oncologic Dispensary
Vitebsk, Belarus
- Institut Jules Bordet
Brussels, Belgium
- Uz Leuven - Campus Gasthuisberg
Leuven, Belgium
- Hospital Centre Liege University_chu Sart Tilman
Liège, Belgium
- Chwapi
Tournai, Belgium
- Clinical Center Banja Luka, Oncology Clinic
Banja Luka, Bosnia and Herzegovina
- University Clinical Hospital Mostar, Oncology Clinic
Mostar, Bosnia and Herzegovina
- Clinical Centre University of Sarajevo
Sarajevo, Bosnia and Herzegovina
- Specialized Hospital for Active Treatment in Obstetrics and Gynecology
Pleven, Bulgaria
- Cross Cancer Institute
Edmonton, Alberta, Canada
- Princess Margaret Cancer Center
Toronto, Ontario, Canada
- Hopital Notre Dame - Chum
Montreal, Quebec, Canada
- Mcgill University
Montreal, Quebec, Canada
- Royal Victoria Hospital
Montreal, Quebec, Canada
- Hotel Dieu de Quebec- Chuq
Québec, Canada
- Masarykův Onkologický Ústav
Brno, Czechia
- Fakultní Nemocnice Olomouc
Olomouc, Czechia
- Všeobecná Fakultní Nemocnice V Praze
Prague, Czechia
- Copenhagen University Hospital "rigshospitalet"
Copenhagen, Denmark
- Herlev Hospital
Herlev, Denmark
- Kuopio University Hospital
Kuopio, Finland
- Tampere University Hospital
Tampere, Finland
- Turku University Central Hospital
Turku, Finland
- Universitätsklinikum Köln
Cologne, Germany
- Klinikum Frankfurt Höchst
Frankfurt, Germany
- Georg-August-Universität Göttingen, Universitäts-Frauenklinik, Abteilung Für Gynäkologie Und Geburtshilfe
Göttingen, Germany
- Universitätsklinik Und Poliklinik Für Gynäkologie Martin Luther Universität Halle-Wittenberg
Halle, Germany
- University Clinic Münster
Münster, Germany
- Klinik Für Frauenheilkunde Und Geburtshilfe Der Universität Regensburg Am Caritas-Krankenhaus St. Josef
Regensburg, Germany
- Mater Misericordiae University Hospital
Dublin, Ireland
- Mater Private Hospital
Dublin, Ireland
- St James'S Hospital
Dublin, Ireland
- University Hospital Galway
Galway, Ireland
- Waterford Regional Hospital
Waterford, Ireland
- Barzilai Medical Center
Ashkelon, Israel
- Rambam Health Care Campus
Haifa, Israel
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Apr 2013
- Primary completion
- 30 Jan 2017
- Completion
- 30 Jan 2017
- Last update posted
- 31 Jul 2018
- Registered enrollment
- 511
- Registry id
- NCT01767155
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.